Vaxxas announced that it began a multi-center Phase I clinical trial of a vaccine against avian flu using its high-density microarray patch. The company develops a vaccine patch based on its proprietary HD-MAP delivery technology. Vaxxas designed … [Read More...] about Vaxxas begins avian flu vaccine trial using high-density microarray delivery patch
Main Content
Sponsored Content
Introduce New Drug Delivery Medical Devices with Lower Risk and Higher ROI
Manufacturing automation is crucial to achieving the precision, quality, and volume required in the medical device industry. Advanced robotics, AI, modular designs, and wireless technology offer the … [Read More...] about Introduce New Drug Delivery Medical Devices with Lower Risk and Higher ROI
Featured Posts
Aptar Pharma inks dev deal with Pulmotree for non-propellant liquid inhaler platform
Aptar Pharma announced that it entered into an exclusive collaboration agreement with Pulmotree to develop a liquid inhaler platform. The collaboration enables Aptar to lead the development and promotion of the Kolibri non-propellant liquid … [Read More...] about Aptar Pharma inks dev deal with Pulmotree for non-propellant liquid inhaler platform
Vaxxas begins avian flu vaccine trial using high-density microarray delivery patch
Vaxxas announced that it began a multi-center Phase I clinical trial of a vaccine against avian flu using its high-density microarray patch. The company develops a vaccine patch based on its proprietary HD-MAP delivery technology. Vaxxas designed … [Read More...] about Vaxxas begins avian flu vaccine trial using high-density microarray delivery patch
Orange Biomed to showcase microfluidic-based A1C test
Orange Biomed announced today that it plans to showcase its microfluidic-based A1C test at the 2024 Diabetes Technology Meeting. The company intends to present research for the device during the event's Startup Showcase next month. It developed … [Read More...] about Orange Biomed to showcase microfluidic-based A1C test
Dexcom CGM worn in outer space on Polaris Dawn mission
Dexcom (Nasdaq:DXCM) announced today that its G6 CGM is being worn by astronauts as part of the Polaris Dawn mission. Polaris Dawn launched this morning with astronauts wearing the G6 to better understand the effects of spaceflight on human … [Read More...] about Dexcom CGM worn in outer space on Polaris Dawn mission
Elutia announces first implant of drug-eluting bioenvelope for pacemakers and neurostimulators
Elutia (Nasdaq:ELUT) announced the first-ever patient implant of its EluPro drug-eluting biologic envelope cleared by the FDA. Dr. John Catanzaro of the East Carolina University Health Medical Center in Greenville, North Carolina, performed the … [Read More...] about Elutia announces first implant of drug-eluting bioenvelope for pacemakers and neurostimulators
Abbott launches Lingo over-the-counter CGM biosensor in the U.S.
Abbott (NYSE:ABT) announced today that it made its Lingo continuous glucose monitoring system available without a prescription in the U.S. The technology is now available in the U.S. at hellolingo.com, as well as in the United Kingdom. Lingo … [Read More...] about Abbott launches Lingo over-the-counter CGM biosensor in the U.S.
Beta Bionics to pair bionic pancreas with Abbott FreeStyle Libre 3 Plus
Beta Bionics announced that it partnered with Abbott (NYSE:ABT) to integrate the company's CGM with its automated insulin delivery system. The companies plan to combine Abbott's FreeStyle Libre 3 Plus continuous glucose monitor (CGM) with the Beta … [Read More...] about Beta Bionics to pair bionic pancreas with Abbott FreeStyle Libre 3 Plus
Embecta wins FDA clearance for disposable insulin patch pump
Embecta (Nasdaq:EMBC) announced today that it received FDA 510(k) clearance for its proprietary disposable insulin delivery system. The open-loop system is indicated for adults who require insulin to manage diabetes, including both type 1 and type … [Read More...] about Embecta wins FDA clearance for disposable insulin patch pump
FDA clears Insulet Omnipod 5 for people with type 2 diabetes
Insulet (Nasdaq:PODD) announced today that the FDA cleared its Omnipod 5 automated insulin delivery for use by people with type 2 diabetes. Clearance makes Omnipod 5, the company's latest-generation AID system, the first and only such system … [Read More...] about FDA clears Insulet Omnipod 5 for people with type 2 diabetes
Dexcom launches Stelo over-the-counter CGM
Dexcom (Nasdaq:DXCM) announced today that it launched its Stelo over-the-counter (OTC) continuous glucose monitor (CGM) biosensor. The San Diego-based company made Stelo available for purchase — without prescription — at Stelo.com. Dexcom became … [Read More...] about Dexcom launches Stelo over-the-counter CGM
In case you missed it
- Former Medtronic acquisition target EOFlow to raise $61.5M, faces Insulet patent infringement lawsuit
- The 9 largest diabetes technology companies in the world
- ICU Medical recalls some infusion pump batteries, updates instructions
- Medtronic wants to be No. 1 in automated insulin delivery as Q1 results highlight Diabetes growth
- Tandem Diabetes Care begins updated software rollout after recall
- Beta Bionics announces 10,000th iLet bionic pancreas user
- Insulet opens new manufacturing plant in Malaysia
- Tandem Diabetes Care to issue app update after more software issues
- ARS Pharmaceuticals wins first FDA approval for needle-free, nasal epinephrine
- Embecta stock gets a boost on Q3 beats, patch pump program remains on track
- Senseonics misses Q2 sales expectations but 365-day CGM is on track for Q4 launch
- Insulet reports Omnipod sales growth of 26% in Q2, raises guidance despite EPS miss
- Medtronic wins FDA nod for next-gen Simplera CGM
- Abbott, Medtronic partner to connect CGM, insulin delivery systems
- Ypsomed closes pen needle, BGM business sale to focus on insulin pump
Clinical Trials
Vaxxas begins avian flu vaccine trial using high-density microarray delivery patch
Vaxxas announced that it began a multi-center Phase I clinical trial of a vaccine against avian flu using its high-density microarray patch. The company develops a vaccine patch based on its proprietary HD-MAP delivery technology. Vaxxas designed its HD-MAP technology to use an ultra-high-density array of micro projections, invisible to the human eye. Applied to […]
CorFlow Therapeutics raises $48.5M for diagnostic, drug delivery platform
CorFlow Therapeutics announced today that it raised €44 million ($48.5 million) to support its novel diagnostic and drug delivery platform. Broadview Ventures and Panakes Partners led the financing round. 415 Capital, Merieux Equity Partners, Merieux Equity Partners, Laerdal Million Lives Fund, Wellington Partners, M&L Investments, Unorthodox Ventures, KOFA Healthcare and Monte Carlo Capital also participated. […]
Eli Lilly has positive once-weekly insulin data
Eli Lilly (NYSE:LLY) today announced positive results from phase 3 clinical trials evaluating its once-weekly insulin efsitora alfa. The Indianapolis-based pharmaceutical giant evaluated its once-weekly insulin in insulin-naïve adults in the QWINT-1 study. These adults have type 2 diabetes and are using basal insulin for the first time. Additionally, Eli Lilly’s QWINT-3 trial looked at […]
Diabeloop study highlights disparities in insulin requirements between sexes
Diabeloop reported results from a real-world study that demonstrated important differences between males and females in insulin requirements. The study evaluated more than 9,000 adults with type 1 diabetes across Europe. It utilized data from patients using the Diabeloop Generation 1 (DBLG1) hybrid closed-loop insulin delivery device. Investigators published findings in the Journal of Diabetes […]
Know Labs data backs non-invasive sensor for glycemic status screening
Know Labs (NYSE:KNW) today shared new data highlighting the use of its non-invasive blood glucose sensor in glycemic status monitoring. The Seattle-based company published its peer-reviewed study in Diabetes Technology & Therapeutics Journal. The published results demonstrated that Know Labs’ proprietary non-invasive radiofrequency (RF) dielectric sensor and trade-secret machine learning (ML) algorithms correctly classified an individual’s glycemic […]
